Diabetes increases the risk of heart failure. This is mainly due to a disease of the blood vessels supplying the heart muscle and/or high blood pressure, but abnormal metabolism may also contribute. We plan to study the mechanisms involved in this abnormal metabolism, whilst also assessing the effects of a drug called Perhexiline which improves the abnormal metabolism that is present in diabetic patients before the development of heart failure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
75
Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
University of Birmingham
Birmingham, Westmidlands, United Kingdom
RECRUITINGThe primary end point of the Perhexiline intervention study will be the change in cardiac PCr/ATP ratio.
Time frame: 2 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.